PMID- 31140154
OWN - NLM
STAT- MEDLINE
DCOM- 20191223
LR  - 20191223
IS  - 1864-6433 (Electronic)
IS  - 0914-7187 (Linking)
VI  - 33
IP  - 8
DP  - 2019 Aug
TI  - Amyloid PET imaging in cardiac amyloidosis: a pilot study using 
      (18)F-flutemetamol positron emission tomography.
PG  - 624-628
LID - 10.1007/s12149-019-01372-7 [doi]
AB  - OBJECTIVE: Cardiac amyloidosis is a rare disease characterized by amyloid heart 
      deposits and is usually a part of systemic amyloidosis, in relation to systemic 
      light chain (AL) and transthyretin (ATTR wild-type or genetic) amyloidosis. 
      Several recent studies suggest a promising role of amyloid PET imaging to image 
      cardiac amyloidosis, and several PET tracers are now available for in vivo 
      detection of amyloid deposits. The aim of this study was to evaluate 
      (18)F-flutemetamol in diagnosing cardiac amyloidosis. METHODS: We performed a 
      pilot study using (18)F-flutemetamol (Vizamyl) in 12 patients, 3 control 
      subjects without cardiac amyloidosis, and 9 subjects with documented cardiac 
      amyloidosis. Mean standardized uptake value (SUV) in the left ventricular 
      myocardium and blood pool was determined and semi-quantitative parameter as 
      target to background ratio (TBR, myocardial/blood pool mean SUV ratio) between 
      10th and 30th minutes was calculated. RESULTS: Uptake of (18)F-flutemetamol in 
      the left ventricular myocardium was noted in all patients with cardiac 
      amyloidosis except one and none in control patient. The TBR was significantly 
      higher in amyloidosis patients than in control subjects: 1.46, interquartile 
      range (IQR) 1.32-2.06 versus 1.06, IQR 0.72-1.1 (p = 0.033). Only one patient in 
      our study had light chain amyloidosis and showed higher TBR than patients with 
      transthyretin amyloid: TBR 3.0 versus TBR median 1.44, IQR 1.33-1.69. CONCLUSION: 
      Amyloid PET tracers such as (18)F-flutemetamol could be a promising tool in 
      diagnosing and in therapy response assessment for patients with cardiac 
      amyloidosis.
FAU - Dietemann, Sebastien
AU  - Dietemann S
AUID- ORCID: 0000-0001-5254-4120
AD  - Department of Nuclear Medicine, Geneva University and University Hospitals of 
      Geneva, Rue Gabrielle Perret Gentil, 4, 1211, Geneva, Switzerland. 
      dietemann.sebastien@gmail.com.
AD  - , 1235 route de Lathoy, 74160, St Julien en Genevois, France. 
      dietemann.sebastien@gmail.com.
FAU - Nkoulou, Rene
AU  - Nkoulou R
AD  - Department of Nuclear Medicine, Geneva University and University Hospitals of 
      Geneva, Rue Gabrielle Perret Gentil, 4, 1211, Geneva, Switzerland.
AD  - Division of Cardiology, University Hospitals of Geneva, Rue Gabrielle Perret 
      Gentil, 4, 1211, Geneva, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20190528
PL  - Japan
TA  - Ann Nucl Med
JT  - Annals of nuclear medicine
JID - 8913398
RN  - 0 (Amyloid)
RN  - 0 (Aniline Compounds)
RN  - 0 (Benzothiazoles)
RN  - 0F3M7032P5 (flutemetamol)
SB  - IM
MH  - Amyloid/*metabolism
MH  - Amyloidosis/*diagnostic imaging/*metabolism
MH  - *Aniline Compounds
MH  - *Benzothiazoles
MH  - Heart Diseases/*diagnostic imaging/*metabolism
MH  - Humans
MH  - Pilot Projects
MH  - *Positron-Emission Tomography
MH  - Retrospective Studies
OTO - NOTNLM
OT  - 18F-flutemetamol
OT  - Cardiac amyloidosis
OT  - PET
EDAT- 2019/05/30 06:00
MHDA- 2019/12/24 06:00
CRDT- 2019/05/30 06:00
PHST- 2019/05/16 00:00 [received]
PHST- 2019/05/21 00:00 [accepted]
PHST- 2019/05/30 06:00 [pubmed]
PHST- 2019/12/24 06:00 [medline]
PHST- 2019/05/30 06:00 [entrez]
AID - 10.1007/s12149-019-01372-7 [pii]
AID - 10.1007/s12149-019-01372-7 [doi]
PST - ppublish
SO  - Ann Nucl Med. 2019 Aug;33(8):624-628. doi: 10.1007/s12149-019-01372-7. Epub 2019 
      May 28.